Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
9.47
-0.80 (-7.79%)
At close: May 22, 2026, 4:00 PM EDT
9.61
+0.14 (1.48%)
After-hours: May 22, 2026, 7:07 PM EDT

Telix Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
3,2512,5375,155---
Market Cap Growth
-41.61%-50.78%----
Enterprise Value
3,5992,8445,062000
Last Close Price
9.477.4915.40---
PE Ratio
--157.79---
PB Ratio
7.836.1114.61---
P/TBV Ratio
7.706.0915.06---
P/FCF Ratio
--112.40---
P/OCF Ratio
--93.76---
EV/EBITDA Ratio
110.87132.84957.91---
EV/FCF Ratio
--110.36---
Debt / Equity Ratio
1.081.080.980.110.120.88
Debt / EBITDA Ratio
21.8221.8268.162.86--
Debt / FCF Ratio
--7.850.53--
Net Debt / Equity Ratio
0.780.78-0.23-0.71-1.32-9.03
Net Debt / EBITDA Ratio
15.1915.19-15.11-17.341.220.48
Net Debt / FCF Ratio
-5.40-5.40-1.74-3.241.490.32
Asset Turnover
-0000.860.05
Inventory Turnover
-00001.24
Quick Ratio
1.171.172.571.141.821.09
Current Ratio
1.431.432.781.412.021.25
Return on Equity (ROE)
-0.00%0.00%0.00%-252.89%-187.51%
Return on Assets (ROA)
-0.00%0.00%0.00%-46.61%-33.17%
Return on Invested Capital (ROIC)
-0.00%0.00%0.00%-121.49%-68.10%
Return on Capital Employed (ROCE)
-0.00%0.00%0.00%-74.58%-42.19%
Earnings Yield
--0.63%---
FCF Yield
--0.89%---
Buyback Yield / Dilution
2.12%2.12%-6.63%-4.21%-10.08%-9.69%
Total Shareholder Return
2.12%2.12%-6.63%-4.21%-10.08%-9.69%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q